Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Wolfe Research

Wolfe Research upgraded shares of Oruka Therapeutics (NASDAQ:ORKA) to a strong-buy rating in a research report released on Monday,Zacks.com reports.

Other research analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, December 20th. Wedbush reissued an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Finally, Stifel Nicolaus assumed coverage on Oruka Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $49.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $39.86.

Oruka Therapeutics Stock Up 0.6 %

Shares of ORKA opened at $14.29 on Monday. The firm’s 50-day moving average price is $18.00. The company has a market capitalization of $500.15 million, a price-to-earnings ratio of -2.28 and a beta of 0.77. Oruka Therapeutics has a 12-month low of $10.95 and a 12-month high of $53.88.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC bought a new stake in Oruka Therapeutics in the 3rd quarter valued at approximately $114,763,000. RTW Investments LP acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $45,359,000. Franklin Resources Inc. bought a new stake in shares of Oruka Therapeutics in the third quarter worth $17,661,000. Braidwell LP acquired a new position in Oruka Therapeutics during the third quarter worth $12,640,000. Finally, Great Point Partners LLC bought a new position in Oruka Therapeutics in the third quarter valued at $12,614,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.